ライフサイエンスコーパス: long-term follow-up

1 atients with Behcet disease, especially with long term follow up.

2 e in the SSIS area is acceptable, even after long-term follow-up.

3 nts included HF alone and death alone during long-term follow-up.

4 treated with the Stanford V regimen and had long-term follow-up.

5 atment surveillance, to ongoing therapy, and long-term follow-up.

6 ot derive clinical benefit with CRT-D during long-term follow-up.

7 h types of TTS showed a similar prognosis at long-term follow-up.

8 management (n=197) at sites participating in long-term follow-up.

9 ntion-to-treat and is continuing for further long-term follow-up.

10 the results of treatment through 4 years and long-term follow-up.

11 3 (77%) <5 kg and 2 of 13 (15%) >5 kg during long-term follow-up.

12 r death from noncardiovascular causes during long-term follow-up.

13 rse arrhythmic and nonarrhythmic events over long-term follow-up.

14 ociated with a low stroke rate at short- and long-term follow-up.

15 nd a greater rate of adverse outcomes during long-term follow-up.

16 ong-standing) persistent/permanent AF during long-term follow-up.

17 s between the randomised treatment groups at long-term follow-up.

18 ated with higher risk of death and HF during long-term follow-up.

19 nts were HF/death and HF events alone during long-term follow-up.

20 l increased risk for cardiovascular death in long-term follow-up.

21 alth perceptions (P = .004) than controls at long-term follow-up.

22 mization is immediate and persistent even at long-term follow-up.

23 lethal arrhythmias in 17% of patients during long-term follow-up.

24 dverse cardiac and cerebrovascular events at long-term follow-up.

25 in larger randomized controlled trials with long-term follow-up.

26 low rates of valve-related complications in long-term follow-up.

27 ently associated with lower mortality during long-term follow-up.

28 s for incident cardiovascular disease during long-term follow-up.

29 le, noninvasive tool for early detection and long-term follow-up.

30 The main study is now completed and is in long-term follow-up.

31 less abstinence within-treatment and during long-term follow-up.

32 iction of conversion from MCI to AD during a long-term follow-up.

33 m total atrial tachyarrhythmia recurrence at long-term follow-up.

34 study within 5 large study populations with long-term follow-up.

35 treatment, but effects were not sustained at long-term follow-up.

36 ction in mortality and morbidity risk during long-term follow-up.

37 epithelial off cross-linking (CXL) during a long-term follow-up.

38 self-expandable metallic stents was noted in long-term follow-up.

39 d no apparent impact on clinical outcomes at long-term follow-up.

40 ogress to proteinuria and CKD or ESRD during long-term follow-up.

41 hospitals across Europe and USA with ongoing long-term follow-up.

42 Myocardial Infarction) were sustained during long-term follow-up.

43 5-11.54; p<0.0001), and was sustained during long-term follow-up.

44 fter initial evaluation seldom emerge during long-term follow-up.

45 a underscores the importance of rebiopsy and long-term follow-up.

46 subgroup of 188 children were enrolled into long-term follow-up.

47 stenosis with durable hemodynamic benefit on long-term follow-up.

48 FAs and suicide mortality over the course of long-term follow-up.

49 coronary artery dissection are common during long-term follow-up.

50 outcome measures, and results at short- and long-term follow-up.

51 e death, myocardial infarction, or stroke at long-term follow-up.

52 or myocardial infarction both at short- and long-term follow-up.

53 tion, stroke, or repeat revascularization at long-term follow-up.

54 f HCM patients with LV apical aneurysms over long-term follow-up.

55 indfulness were not significant at short- or long-term follow-up.

56 initial assessment and in 10%-15% even after long-term follow-up.

57 ssociated with stable visual outcomes during long-term follow-up.

58 ation to aggressive lymphoma (4%), requiring long-term follow-up.

59 n, closed), and time between steps through a long-term follow-up.

60 treatment but 54 patients were continuing in long-term follow-up.

61 ains lower than that in patients with NFM at long-term follow-up.

62 cal prognostic factors related to IBTR using long-term follow-up.

63 ave a high probability of progressing during long-term follow-up.

64 a woman's preferences, with a commitment to long-term follow-up.

65 receiving noninvasive ventilation including long-term follow-up.

66 e antigen (HBsAg), with 20% HBsAg loss after long-term follow-up.

67 s in a large, randomized clinical trial with long-term follow-up.

68 with IVF reveal a specific diagnosis during long-term follow-up.

69 nterventions (21.6% vs 3.6%; P = .03) during long-term follow-up.

70 ss, and thus facilitate a personalization of long-term follow-up.

71 to hand or forearm symptoms, even at a very-long-term follow-up.

72 ith similar risk of target-vessel failure at long-term follow-up.

73 Three patients (5%) developed cysts at long-term follow-up, 1 of whom developed radionecrosis r

74 A minority of patients developed cysts at long-term follow-up, 1 of whom had permanent neurologica

75 x PEG-IFNa-treated patients until the end of long-term follow-up (10%).

76 with a new prospective cohort and report the long-term follow-up (10-years) using an intention-to-tre

77 At long-term follow-up, 24.7% (95% confidence interval (CI)

78 During long-term follow-up (46+/-29 months), all patients with

79 Between day 30 and long-term follow-up, 65 deaths occurred in the thromboly

80 BT and GET seen at 1 year were maintained at long-term follow-up a median of 2.5 years after randomis

81 all studies comparing ASA with myectomy with long-term follow-up, (aborted) sudden cardiac death and

82 Long-term follow-up after a clinical trial of 2 often-us

83 utcome remains excellent in most patients at long-term follow-up after cardiomyotomy for achalasia.

84 ents than the control population, warranting long-term follow-up after congenital cardiac surgery.

85 We emphasize the need for regular and long-term follow-up after pediatric cataract surgery.

86 ontrolled trial, and observational posttrial long-term follow-up, after excluding individuals with ev

87 This long-term follow-up analysis evaluated overall survival

88 This long-term follow-up analysis was performed to determine

89 rom patients' bone marrow plasma cells, with long-term follow-up and clinicopathological data.

90 gene expression analysis of the tumour, with long-term follow-up and complete clinicopathological dat

91 Larger sample sizes, long-term follow-up and designs including blinded sham c

92 Larger leadless pacing trials, with long-term follow-up and direct randomized comparison wit

93 Long-term follow-up and management of donors was underta

94 n apparently "cured" patients could optimize long-term follow-up and modify decision-making regarding

95 e associated with cardiovascular outcomes in long-term follow-up and provide incremental value over t

96 rior to AMIO in achieving freedom from AF at long-term follow-up and reducing unplanned hospitalizati

97 hermore, data from longitudinal studies with long-term follow-up and repeated anthropometric measures

98 hemangiomas that demonstrated growth during long-term follow-up and the annual growth rate of those

99 e of the potential for cardiotoxicity during long-term follow-up and to consider both prevention and

100 of psychosocial therapy after short-term and long-term follow-up, and a protective effect for suicide

101 Although malnutrition is well described in long-term follow-up, and gastrointestinal symptoms are c

102 ta, no published data from large trials with long-term follow-up, and limited quality and incomplete

103 ted with delayed HBeAg seroconversion during long-term follow-up, and more HBV genotype C infection a

104 acy of new-generation drug-eluting stents at long-term follow-up, and specifically in patients with S

105 prospective human intervention studies with long-term follow-up are available.

106 Results of large trials with long-term follow-up are critically needed to establish t

107 Complementary trials with long-term follow-up are needed.

108 e and physical functioning, respectively, at long-term follow-up as compared with 1 year: CBT -2.2 [9

109 Median time from randomisation to return of long-term follow-up assessment was 31 months (IQR 30-32;

110 A long-term follow-up assessment was undertaken for patien

111 ases occurred between the postdeployment and long-term follow-up assessments, which suggests that adv

112 odies in case of DSA positivity after LT and long-term follow-up at our institution.

113 noma, and visual impairment is common during long-term follow-up, but some useful vision can be prese

114 r outcome and were similar to CBT and GET at long-term follow-up, but these data should be interprete

115 normal skin color and texture, with regular long-term follow-up by a dermatologist or gynecologist.

116 Long-term follow-up by way of a contrast-enhanced CT rev

117 at age 2.8 years transferred his care to the long-term follow-up clinic.

118 n the low incidence of late recurrences with long-term follow-up, CMT can be considered as an alterna

119 improved in the early intervention group at long-term follow-up compared with the control group (ant

120 n the study group had neurologic sequelae at long-term follow up, compared with 13 (14.1%) in the con

121 In long-term follow-up, compared with BMS, DES use was safe

122 Long-term follow-up continues.

123 ECG and clinical parameters, sinus rhythm at long-term follow-up could be predicted with a mean AUC o

124 nts with CA and GAD65-Abs, including 25 with long-term follow-up data (median, 5.4 years; interquarti

125 Long-term follow-up data and health-economic assessments

126 Long-term follow-up data and tissue samples were obtaine

127 with HER2-positive early breast cancer, but long-term follow-up data are needed.

128 Long-term follow-up data are still needed; in the end, p

129 Such long-term follow-up data can usefully inform on the pote

130 Long-term follow-up data for disease recurrence and surv

131 This study used population-based, long-term follow-up data from national registries to foc

132 Here, we report long-term follow-up data from study CA209-004, including

133 Here we describe long-term follow-up data from three treated patients.

134 Conclusion Long-term follow-up data of the four randomized trials l

135 Nevertheless, long-term follow-up data of the leading bioresorbable sc

136 n's vaccination status was unknown, and that long-term follow-up data on disease detection in screen-

137 ng home admissions), and the availability of long-term follow-up data on mortality for analysis only

138 Long-term follow-up data suggest both efficacy and safet

139 Long-term follow-up data were available for 58 out of 77

140 Long-term follow-up data were obtained for all patients

141 Long-term follow-up data were scarce.

142 rt-term outcomes, but there are no published long-term follow-up data.

143 Here we report long-term follow-up data.

144 on were similar to those obtained when using long-term follow-up defined carrier status for predictio

145 This large case series with long-term follow-up demonstrates the incidence of bleb-r

146 progression of microvascular outcomes in the long-term follow-up Epidemiology of Diabetes Interventio

147 At long-term follow-up, esophagitis was found in 14 group A

148 ave been focused on technical analyses and a long-term follow-up, especially on thrombotic total occl

149 ily cited early childhood interventions with long-term follow-up evaluated by the method of randomiza

150 rate, complications and clinical results in long term follow up for computed tomography (CT)-guided

151 n inform guideline-based recommendations for long-term follow-up for cataract.

152 Long-term follow-up for events and survival continues.

153 and 120 days) and ipsilateral stroke during long-term follow-up for patients assigned to CAS or CEA.

154 AKI progression and advocate the utility of long-term follow-up for patients with this disease.

155 Lacking are data on short- and long-term follow-up from population-based studies to est

156 mary kidney-alone transplant recipients with long-term follow-up, GFNC and other graft loss causes we

157 ort-term follow-up group to 92% (11%) in the long-term follow-up group (P < .001).

158 patients undergoing noncardiac surgery (the long-term follow-up group), and we compared the findings

159 6.8 events per 100 hours of oximetry for the long-term follow-up group; P = .10).

160 Between the short- and long-term follow-up groups, the complication rate decrea

161 d concordance with Children's Oncology Group Long-Term Follow-Up Guidelines in response to a clinical

162 sensus-based Children's Oncology Group (COG) Long-Term Follow-up Guidelines recommend lifetime echoca

163 ance recommendations vary among the existing long-term follow-up guidelines, which impedes the implem

164 s adopted from the Children's Oncology Group Long-Term Follow-Up Guidelines.

165 Using data from detailed Gulf Long-term Follow-up ( GuLF) Study enrollment interviews,

166 Long-term follow-up has been lacking.

167 Long-term follow-up has now been completed, with the fin

168 Initial results of long-term follow-up have found a survival benefit in thi

169 this was not significant after adjustment on long-term follow-up (hazard ratio, 1.00; 95% confidence

170 At long-term follow-up in 28 patients at a median of 17.2 (

171 ite extensive literature, few studies report long-term follow-up in cohorts with adequate retention r

172 We describe baseline characteristics and long-term follow-up in patients who experienced CR with

173 sion capable of predicting abstinence during long-term follow-up in patients with AH.

174 BG + OMT reduced the primary endpoint during long-term follow-up in patients with type 2 diabetes and

175 present to the ED with chest pain is safe at long-term follow-up, including patients discharged after

176 The long-term follow-up indicated that, in selected cases of

177 We report the results of long-term follow-up interim analyses and integrated effi

178 Therefore, long-term follow-up is generally recommended.

179 Long-term follow-up is important to judge both efficacy

180 Long-term follow-up is necessary for these patients, and

181 Long-term follow-up is needed to clarify this issue.

182 Long-term follow-up is needed to determine the visual si

183 Long-term follow-up is needed to determine whether some

184 eferral for patients on dialysis in Georgia; long-term follow-up is needed to determine whether these

185 Long-term follow-up is needed to establish durable oncol

186 Metastases have been observed, and long-term follow-up is needed.

187 tment and active treatment is completed, but long-term follow-up is ongoing.

188 At long-term follow-up (mean, 6.2 years +/- 2.5), treatment

189 s diagnosed by CNB received observation with long-term follow-up (mean, 8 years).

190 On long-term follow-up (median 2.3 years) recurrent SCAD oc

191 During long-term follow-up (median of 24 months), mortality was

192 At long-term follow-up (median, 2.9 years), PCI was associa

193 Over long-term follow-up (median, 867 days), arrhythmia-free

194 From the time of surgery to long-term follow-up (median, 9.3 postoperative years), t

195 lesion features associated with MACE during long-term follow-up (median: 1115 days) were determined

196 During long-term follow-up, multivariate predictors of mortalit

197 ogous, NCT00968760; allogeneic, NCT01497184; long-term follow-up, NCT01492036.

198 enty-two of 33 patients (67%) with available long-term follow-up neurocognitive testing had severe im

199 Limitations of the study include the lack of long-term follow-up, non-blinding of service providers a

200 In this very long-term follow-up observational study of obese patient

201 We present a long term follow-up of a young female patient with choro

202 We now report the long-term follow-up of 10 patients infused with such saf

203 Long-term follow-up of 1202 patients (TT1: n = 231, medi

204 We reviewed acute and long-term follow-up of 21 patients (14 males) referred f

205 The study was a retrospective analysis with long-term follow-up of 62 patients with a minimum tumor-

206 We present long-term follow-up of a dasatinib phase 3 study of pati

207 ed the effect of NVAS on atopy by conducting long-term follow-up of a previous randomized controlled

208 igate the clinical features, management, and long-term follow-up of children with drug-induced Brugad

209 Long-term follow-up of donors has demonstrated end-stage

210 vestigate clinical features, management, and long-term follow-up of ICD therapy in patients with Brug

211 During long-term follow-up of MADIT-CRT study patients with LBB

212 its of IVTA therapy and also of the need for long-term follow-up of participants at risk for this com

213 We report the long-term follow-up of patients in this UK cohort.

214 Long-term follow-up of patients receiving tumor-infiltra

215 ealth-related quality of life are lacking in long-term follow-up of patients who remain cancer free a

216 ve coronary angiography in the diagnosis and long-term follow-up of patients with KD, especially when

217 Also, long-term follow-up of patients with TTP is crucial to i

218 Long-term follow-up of population-based randomized, cont

219 Long-term follow-up of randomized nutritional trials is

220 Long-term follow-up of recipients on belatacept has demo

221 We present the long-term follow-up of SCA children from the Creteil new

222 e best conditioning regimen, and the optimal long-term follow-up of such patients especially regardin

223 In a long-term follow-up of the CoBalT trial, we examined the

224 Conclusion With an 83% 8-year OS rate, long-term follow-up of the FOLL05 trial confirms the fav

225 We report the long-term follow-up of the IBIS-I trial, in which the pa

226 Providing long-term follow-up of the natural history of age-relate

227 Herein, we present the long-term follow-up of the randomized CLL8 trial reporti

228 initial presentation, mandating the need for long-term follow-up of these children.

229 Long-term follow-up of these patients suggests that RALD

230 remained significantly increased, even after long-term follow-up of up to 20 years.

231 d efficacy data on a further 18 patients and long-term follow-up on the entire cohort of 43 patients.

232 Assessments took place at midterm and long-term follow-up, on average 6 and 12 years after his

233 h 20 or fewer cases were excluded or were of long-term follow-up only, because this may reflect gende

234 beyond 5 years after diagnosis, we analysed long-term follow-up outcomes of this trial.

235 ns relative to primary outcomes at short- or long-term follow-up (p > .05).

236 Here we report, with a long-term follow-up period (>10 years) efficacy and safe

237 Data collection during the long-term follow-up period took place from May 25 to Jul

238 emic safety signals were observed during the long-term follow-up period.

239 hythmias and the need for reoperation during long-term follow-up pose significant management challeng

240 Of these, 248 individuals completed a long-term follow-up questionnaire and provided data for

241 immunologic assessments were performed, and long-term follow-up questionnaires (LFQs) were administe

242 In this large population-based study with a long-term follow-up, reduced FEV1 and obstructive respir

243 Limitations of the study include no long-term follow-up, reliance on self-report rather than

244 le in these devices, indicating that careful long-term follow-up remains important even after CoCr-EE

245 To date there have been no long-term follow-up reports of what is for many a contro

246 At long-term follow-up (results of which were available for

247 gs on this large cohort of XP patients under long-term follow-up reveal that XP is more heterogeneous

248 Long-term follow-up showed no deaths or major late compl

249 From baseline to long-term follow-up, significant declines were recorded

250 During long-term follow-up, stenting was associated with an inc

251 Our findings suggest that, during long-term follow-up, strict BP control does not delay th

252 Long-term follow-up studies are needed to confirm these

253 ve shown good to excellent results; however, long-term follow-up studies are scarce, retrospective, a

254 is the surgical standard for HD, controlled long-term follow-up studies evaluating bowel function an

255 is the surgical standard for HD, controlled long-term follow-up studies evaluating bowel function an

256 Long-term follow-up studies investigating whether elevat

257 The lack of long-term follow-up studies, including pathologic data,

258 Should our results be confirmed by long-term follow-up studies, POEM may become one of the

259 existing hypertension justifies the need for long-term follow-up studies.

260 fetime Cohort Study (SJLIFE) and the St Jude Long-term Follow-up Study (SJLTFU).

261 This long-term follow-up study aimed to assess the prognosis

262 In this long-term follow-up study among Nordic twins, there was

263 In a long-term follow-up study of 906 5-year hereditary Rb su

264 In conclusion, in this long-term follow-up study of older adults, domestic work

265 We used data from the Gulf Long-term Follow-up Study, a cohort of workers and volun

266 r PEG-IFNa treatment who were entered in the long-term follow-up study.

267 At long-term follow-up, survivors were an average of 13.8 y

268 orable neurologic outcome was more likely at long-term follow-up than at hospital discharge for both

269 and death, HF alone, and death alone during long-term follow-up than patients with discordant or les

270 With long-term follow-up, the benefits attributable to mesh a

271 At long-term follow-up, the CFCs decreased in size and numb

272 With long-term follow-up, the cumulative incidence of microva

273 During long-term follow-up, the rate of major adverse cardiac a

274 f age needs to be carefully monitored during long-term follow-up, the risk among children 2 to 16 yea

275 In this large single-institution cohort with long-term follow-up, the risk of transformation was lowe

276 S group (35% vs. 14%; P = 0.035), but during long-term follow-up this difference diminished (38% vs.

277 hort of patients with (18)F-FDG-avid TI with long-term follow-up to assess the validity of this appro

278 ies have used comprehensive patient data and long-term follow-up to examine factors that predict MCC

279 targeted with early interventions and active long-term follow-up to prevent, detect, and alleviate ps

280 During long-term follow-up, transatrial repair of tetralogy of

281 work, we thoroughly studied and subjected to long-term follow-up two macaques showing intermittent co

282 longitudinal cohort of 66 MS patients with a long-term follow-up (up to 20 years).

283 transplant exosomes in recipient blood over long-term follow-up using anti-HLA antibody, which was d

284 sed by compliant patients who attend regular long-term follow-up visits may modify the course of the

285 % of the surgeon's time dedicated to routine long-term follow-up visits.

286 Median long-term follow-up was 3.1 years, and overall major adv

287 Functional long-term follow-up was evaluated by a gastrointestinal/

288 Long-term follow-up was included in the third protocol a

289 Long-term follow-up was not presently available in this

290 Long-term follow-up was performed to document the occurr

291 In this long-term follow-up, we sent postal questionnaires to as

292 Patients eligible for the long-term follow-up were those who had not withdrawn by

293 ily life, immediately after treatment and at long-term follow-up, whereas there is no evidence for th

294 p, and a protective effect for suicide after long-term follow-up, which favour the use of psychosocia

295 tion with an AUC of 0.70 and sinus rhythm at long-term follow-up with an AUC of 0.61.

296 -treated (14%) patients during posttreatment long-term follow-up with an overall annual event rate of

297 Differences in survival persisted over long-term follow-up, with 5-year survival rates of 85% o

298 trials and large observational studies with long-term follow-up, with or without a control group.

299 DV RNA-positive at least once during further long-term follow-up, with seven patients being HDV RNA-p

300 Over long-term follow-up, younger and middle-aged adults with